FDA panel votes in favor of Daiichi Sankyo’s blood thinner drug overwhelmingly

October 31, 2014 7:39 PM

5 0

Japanese drug maker Daiichi Sankyo Co’s blood thinner has been approved by a U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee by a 9-1 vote. Their blood thinner, called edoxaban, can now be used on patients with nonvalvular atrial fibrillation. That is a type of arrhythmia (rapid, irregular heartbeat) which can cause a stroke. Edoxaban (Savaysa) is a once a day anticoagulant which checks the Factor Xa, a protein which can affect the process of blood clotting significantly.

Edoxaban will now have to compete with three other drugs (Xarelto, sold by Bayer AG and Johnson & Johnson; Eliquis, sold by Bristol-Myers Squibb Co and Pfizer Inc, and Pradaxa, made by privately held Boehringer Ingelheim) which are already in queue as a replacement to a treatment which has been foll...

Read more

To category page

Loading...